Changes in Inflammatory Bowel Disease Subtype During Follow-up and over Time in 44,302 Patients
Overview
Authors
Affiliations
Aim: To investigate inflammatory bowel disease (IBD) register-based subtype classifications over a patient's disease course and over time.
Methods: We examined International Classification of Diseases coding in patients with ≥2 IBD diagnostic listings in the National Patient Register 2002-2014 (n = 44,302).
Results: 18% of the patients changed diagnosis (17% of adults, 29% of children) during a median follow-up of 3.8 years. Of visits with diagnoses of Crohn's disease (CD) or ulcerative colitis (UC), 97% were followed by the same diagnosis, whereas 67% of visits with diagnosis IBD-unclassified (IBD-U) were followed by another IBD-U diagnosis. Patients with any diagnostic change changed mostly once (47%) or twice (31%), 39% from UC to CD, 33% from CD to UC and 30% to or from IBD-U. Using a classification algorithm based on the first two diagnoses ('incident classification'), suited for prospective cohort studies, the proportion adult patients with CD, UC, and IBD-U 2002-2014 were 29%, 62%, and 10% (43%, 45%, and 12% in children). A classification model incorporating additional information from surgeries and giving weight to the last 5 years of visits ('prevalent classification'), suited for description of a study population at end of follow-up, classified 31% of adult cases as CD, 58% as UC and 11% as IBD-U (44%, 38%, and 18% in children).
Conclusions: IBD subtype changed in 18% during follow-up. The proportion with CD increased and UC decreased from definition at start to end of follow-up. IBD-U was more common in children.
Malmquist M, Voghera S, Berg S, Saalman R, Olen O J Crohns Colitis. 2025; 19(2).
PMID: 39804716 PMC: 11791680. DOI: 10.1093/ecco-jcc/jjaf007.
Lee S, Shin M, Kim S, Kim S, Yoon H, Park Y Pediatr Gastroenterol Hepatol Nutr. 2024; 27(4):206-214.
PMID: 39035400 PMC: 11254648. DOI: 10.5223/pghn.2024.27.4.206.
Yang Y, Ludvigsson J, Forss A, Faucon A, Faye A, Olen O Clin Gastroenterol Hepatol. 2024; 22(11):2291-2298.e17.
PMID: 38777172 PMC: 11512676. DOI: 10.1016/j.cgh.2024.05.010.
Petit P, Leroyer A, Chamot S, Fumery M, Bonneterre V J Crohns Colitis. 2024; 18(9):1415-1429.
PMID: 38605515 PMC: 11369074. DOI: 10.1093/ecco-jcc/jjae050.
Predictive biomarkers for anti-TNF alpha therapy in IBD patients.
Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S J Transl Med. 2024; 22(1):284.
PMID: 38493113 PMC: 10943853. DOI: 10.1186/s12967-024-05058-1.